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ABSTRACT 
Background:Ayurveda arrangement of solution was very valued and worked on amid the brilliant time of Indian history. Three unique 
measurements of lauhabhasma were assessed for the haematinic movement and contrasted and that of Ferrous sulfate. The outcomes 
recommend that lauhabhasmas indicates noteworthy haematinic movement. Aim: The present study was designed as standardization of an 
Ayurvedic Bhasma preparation and its evaluation as a potential Haematinic Agent. Materials and Methods: It was evaluated by the terms of 
physiochemical parameters including colour, odour, taste, pH, total ash, acid insoluble ash, loss on drying, particle size determination, 
determination of floating property and determination of fineness and metallic luster in direct sunlight. For the pharmacological evaluations, rats 
were divided into 6 groups and administered as follows. Group 1: 1% Acacia; Group 2: 1% Acacia glue containing 1ml of supreme liquor for each 
50 ml; Group 3: 1 ml of oral single dosage of 20mg/kg body weight/day ferrous sulfate; Group 4: I ml of oral single dosage of 10 mg/kg body 
weight/day of lauhabhasma; Group 5: 1 ml of oral single dosage of 15 mg/kg body weight/day of lauhabhasma and Group 6: 1 ml of oral single 
dosage of 20 mg/kg body weight/day of lauhabhasma. It was examined by different parameters such as RBCs, WBCs (Monocyte, Basophil, 
Eosinophil, lymphocytes) count, PCV, MCV, hemoglobin value, Mean Cell Hemoglobin Concentration (MCHbC) and Mean cell hemoglobin 
(MCHb).Results: In all the parameters, Ayurvedic preparation exhibited a potential hematinic effect. Conclusion:In conclusion, this examination 
may infer that the lauhabhasma might be exceptionally compelling ayurvedichaematinic operator and can be helpful in treatment of iron 
deficiency.Future aspect: In future, it might be a well-researched and promising source to subside anemia and various blood disorders.  
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INTRODUCTION 
Ayurveda arrangement of solution was very valued and 
worked on amid the brilliant time of Indian history. This 
arrangement of meds perceives the significance of metallic 
smaller scale supplements in our body. Lack or lopsidedness 
of these metallic small scale supplements in body brings 
about the indication of ailments. This idea has incredible 
significance in show day circumstance as our reality faces 
major natural unsettling influences and therefore more up to 
date infections. Ayurveda lays more accentuation on the 
counteractive action and treatment of illnesses by keeping a 
harmony amongst eating regimen and way of life of an 
individual relying on the earth he or she lives in. The need of 
metallic smaller scale supplements for idealize wellbeing is a 
subject for escalated contemplate 1,2. Customary 
pharmaceuticals are utilized as a part of the treatment of 
different interminable issue and for the change of prosperity 
of people. In Ayurveda, metals, for example, Iron, Copper, 
Zinc, and Lead, and so on., are utilized as a part of numerous 
arrangements, in the wake of changing the metals into 
nonmetallic structures. The solutions so arranged are 
ordered under a gathering called Rasauṣadhis. Rasauṣadhis 
have been endorsed by Ayurvedic doctors since long with 
uncommon notices of danger. Bhasmas are one of a kind 
arrangements including metallic/mineral arrangements 
calcined utilizing warmth to change metals into non lethal 
organometallic shapes. In arrangements of these Bhasmas, 
the starter procedure which causes detoxification without 
hurting its restorative properties (guṇas) is called as 
'Śodhana'. The present investigation was intended to set up 
the lethality profile of Bhasma 3. Weakness is a condition 
portrayed by diminish in the aggregate sum of red platelets 
(RBCs) or hemoglobin in the blood underneath the typical 
range for the given age and sex of the patient. This by and 
large outcomes in brought capacity of the blood down to 
convey oxygen. The ordinary scope of hemoglobin in females 
is 14±2.5 g/dl, in guys is 15.5±2.5g/dl and in newborn 
children is 16.5±3 g/dl. It can be caused by any condition 
bringing about a huge reduction in the aggregate body 
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erythrocyte mass. Ayurvedic treatment of diabetes 
incorporates a few home grown medications and 
furthermore a couple of mineral arrangements including 
bhasmas. LauhaBhasma is the most as often as possible 
utilized Ayurvedic arrangement of metallic iron. It is one of 
the old arrangements for press suppliments and can be set 
up by established and additionally mechanical strategies 4. 
Bhasma are remarkable ayurvedic metallic/minerals 
readiness, treated with home grown juice or decoction and 
uncovered for Ayurveda, which are known in Indian 
subcontinent since 7thcentury A.D. what's more, generally 
suggested for treatment of an assortment of unending 
diseases. Creature's subsidiary, for example, horns, shells, 
quills, metallic, nonmetallic and herbals are ordinarily 
managed as Bhasma 5. Ayurveda is one of the most seasoned 
frameworks of prescription, honed in Indian sub-landmass. 
Ayurveda is a settled investigation of antiquated Indian 
legacy. The word Ayurveda infers the signifying 
"investigation of life". This science is trusted and built up 
through a great many years. At the season of Charaka and 
Sushuruta restorative plants were fundamentally utilized for 
the planning of therapeutic operators6. 
MATARIALS AND METHODS 
1. Physical standardization 
Determination of aggregate fiery debris, Determination of 
misfortune on drying and Determination of pH. 
2. Pharmacological Studies 
Here the examples are tried for particular pharmacological 
action utilizing creature models. 
i) Animals  
Swiss mice of either sex weighing around 18g (youthful ones, 
matured two months) and 25g (more established ones, 
matured 28 weeks) will be utilized as a part of the present 
investigation. The creature will be acquired from infection 
free little creature house. They will be acclimatized to the 
research center conditions for 5 days before social 
investigations. The creatures had free access to sustenance 
and water and will be kept up under 12:12 hours light and 
dull cycles. Every one of the readings will be taken amid a 
similar time i.e. between 6-8 PM. Institutional Animals Ethics 
Committee(IAEC) had endorsed the exploratory convention 
and care of creatures was taken according to the CPCSEA 
rules, Animal welfare division, Ministry of Environment and 
timberland, Govt. of India. The creatures will be kept in 
polypropylene confines under standard research facility 
condition. The creature house will be kept up at 27°c ±2°c 
temperature and 50 to 60% mugginess. The creatures will be 
gotten from CPCSEA endorsed creature place of 
establishment. 
ii) Acute oral toxicity study 
 Intense danger contemplates were led to decide the 
protected dosage according to OECD-423 rules. Medications 
were regulated orally to medium-term fasted creatures. 
After medication organization the creatures were watched 
constantly for 60 minutes, oftentimes for the following four 
hours, and afterward following 24 hours. After organization, 
Irwin's test was directed, where the creatures were watched 
for net social changes. The dangerous dosage was dictated by 
watching the death rate in the medication treated gatherings. 
From this the helpful measurements was chosen for the 
further investigation. 
iii) Planning of measurements  
Promoted arrangements of Lauhabhasma were acquired 
from neighborhood ayurvedic medicinal market. Phenyl 
hydrazine and ferrous sulfate were acquired from SD Fine 
Chemicals, Mumbai, India. Every other substance were 
utilized of AR review and utilized as got.  
The dosage for exploratory investigation of the medications 
was figured by extrapolating the human measurements to 
creature dosage in view of the body surface territory 
proportion. Medication suspension was set up in 1% gum 
acacia arrangement in water and arrangement of phenyl 
hydrazine was set up by dissolving it in total liquor (50mg of 
every 1ml) and including acacia suspension 4,7. Every single 
other concoction utilized for think about were obtained from 
rumored Indian providers and will be of AR review.  
3. Experimental Design 
Group 1: Normal Control Group (1% acacia glue containing 
1ml of total liquor for every 50 ml). 
Group 2: Anemic Control Group (1% acacia glue containing 
1ml of supreme liquor for each 50 ml).  
Group 3: Standard Group (1ml of 20mg/kg body weight/day 
ferrous sulfate).  
Group 4: Test Group 1 (1ml of the 10 mg/kg body 
weight/day of lauhabhasma).  
Group 5: Test Group 2 (1ml of the 15 mg/kg body 
weight/day of lauhabhasma).  
Group 6: Test Group 3 (1ml of 20 mg/kg body weight of 
lauhabhasm).  
4. Inspecting Schedule  
The examination was done for 21 days. The blood (1-2ml) 
was pulled back in EDTA from the retro-orbital plexus, under 
slight chloroform anesthesia, on day 0 preceding phenyl 
hydrazine organization, and on days 1, 7, 14 and 21, days 
after phenyl hydrazine organization i.e. acceptance of 
paleness.  
5. Assessment of hematological parameters   
The hematinic movement was assessed by surveying 
different blood parameters like red platelet (RBC) tally, 
hemoglobin (HB) fixation and stuffed cell volume (PCV). The 
mean cell volumes (MCV), mean cell hemoglobin (MCH), 
mean cell hemoglobin focus (MCHC) and white platelets 
(WBC) tally. The parameters were dictated by utilizing Auto 
cell counter 920E (Swelab Ltd) (8,9). 
RESULT 
A. Physical standardization 
Determination of Total, Acid soluble and water soluble 
ash value 
Table 1 depicts the determination of total ash, acid soluble 
and water soluble ash values found in the ayurvedic 
preparation as potent hematinic agent. 
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Table 1: Determination of Total, Acid soluble and water soluble ash value 
Substance Total ash (%) Acid soluble (%) Water soluble (%) 
Ayurvedic formulation 11.24 7.29 3.95 
 
Determination of Loss on Drying (LOD)  
Table 2 depicts the loss on drying of the substance.  
Table 2: Determination of LOD 
Substance Weight of formulation (g) Loss on drying (g) 
Ayurvedic formulation 3.5 0.8 
 
B. Pharmacological evaluation 
Acute oral toxicity test 
Table 3: Acute oral toxicity test 
S.N. Treatment Mortality Observation 
0 Days 7 Days 14 Days 
1. Control group 
(Distilled water) 
No toxic, behavioural& 
mortality  changes observed 
No toxic, 
behavioural& 
mortality  changes 
observed 
No toxic, behavioural& 
mortality  changes 
observed 
2. Test group (herbal 
formulation 
5000mg/kg) 
No toxic, behavioural& 
mortality  changes observed 
No toxic, 
behavioural& 
mortality  changes 
observed 
No toxic, behavioural& 
mortality  changes 
observed 
 
Determination of RBC Count  
The following table depicts the determination of RBC Count- 
Table 4: RBC Count 
S.N. Treatment 
(Group) 
RBC Count[Million (cells/mcL)±SEM] 
1st day   7thday   14th day  21th day 
1. Normal Control 6.3±0.2 6.3±0.4 6.6±0.1 6.8±0.7 
2. Anemic Control 6.2±0.1 6.2±0.3 5.8±0.7 5.2±0.5 
3. Standard (20mg/kg) 6.4±0.4 6.8±0.4 7.6±0.1 7.9±0.7 
4. Test 1 (10mg/kg) 6.2±0.6 6.3±0.5 6.7±0.7 6.8±0.4 
5. Test 2 (15mg/kg) 6.3±0.1 6.3±0.7 6.8±0.4 7.1±0.6 
6. Test 3 (20mg/kg) 6.4±0.5 6.6±0.8 6.9±0.1 7.6±0.8 
 
Estimation of hemoglobin count 
The hemoglobin concentration was observed by Sahli’s method and depicted in the table mentioned below- 
 
Table 5: Estimation of hemoglobin level 
S.N. Treatment 
(Group) 
Hemoglobin level (g/100ml±SEM) 
 1st day           7thday            14th day         21th day 
1. Normal Control 13.2±0.2 13.3±0.5 13.8±0.6 14.1±0.2 
2. Anemic Control 12.8±0.6 12.1±0.7 11.8±0.8 11.5±0.4 
3. Standard (20mg/kg) 12.4±0.5 13.6±0.8 13.9±0.3 14.8±0.1 
4. Test 1 (10mg/kg) 12.5±0.2 12.6±0.4 12.8±0.7 13.6±0.1 
5. Test 2 (15mg/kg) 12.4±0.8      12.8±0.4 13.2±0.6 13.7±0.7 
6. Test 3 (20mg/kg) 12.3±0.1 13.1±0.2 13.6±0.7 14.2±0.3 
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Determination of Packed Cell Volume (PCV) 
Table 6: Determination of PCV 
S.N. Treatment 
(Group) 
PCV  (Percentage± SEM) 
 1st day           7thday            14th day         21th day 
1. Normal Control 42.2±0.2 42.8±0.6 42.6±0.8 44.9±0.1 
2. Anemic Control 41.2±0.3 41.4±0.6 38.2±0.7 41.8±0.9 
3. Standard (20mg/kg) 44.6±0.1 46.9±0.2 47.6±0.4 49.6±0.7 
4. Test 1 (10mg/kg) 41.5±0.5 42.2±0.2 45.6±0.7 46.7±0.1 
5. Test 2 (15mg/kg) 42.2±0.2 42.2±0.7 43.5±0.9 44.1±0.3 
6. Test 3 (20mg/kg) 44.3±0.1 44.9±0.3 47.2±0.5 48.1±0.9 
 
Determination of Mean Cell Volume (MCV) 
Table 7: Determination of MCV 
S.N. Treatment 
(Group) 
MCV  (Pg± SEM) 
 1st day           7thday            14th day         21th day 
1. Normal Control 20.2±0.2 20.5±0.3 20.9±0.5 21.2±0.4 
2. Anemic Control 19.8±0.4 20.3±0.8 19.4±0.6 18.6±0.4 
3. Standard (20mg/kg) 20.6±0.4 22.9±0.2 23.3±0.1 23.8±0.3 
4. Test 1 (10mg/kg) 19.5±0.7 19.9±0.5 20.8±0.7 21.7±0.1 
5. Test 2 (15mg/kg) 20.2±0.6 21.2±0.6 22.5±0.3 22.1±0.1 
6. Test 3 (20mg/kg) 20.3±0.4 21.3±0.7 22.2±0.4 22.5±0.8 
 
 
Determination of Mean Cell Hemoglobin (MCHb) 
Table 8: Determination of MCHb 
S.N. Treatment 
(Group) 
MCHb  (Pg± SEM) 
 1st day           7thday            14th day         21th day 
1. Normal Control 20.2±0.1 20.5±0.7 20.9±0.8 21.2±0.2 
2. Anemic Control 19.8±0.7 20.3±0.4 19.4±0.7 18.6±0.1 
3. Standard (20mg/kg) 20.6±0.5 21.2±0.2 22.3±0.7 22.8±0.8 
4. Test 1 (10mg/kg) 19.5±0.4 19.9±0.8 20.8±0.4 21.7±0.1 
5. Test 2 (15mg/kg) 20.2±0.1 21.2±0.7 22.5±0.3 22.1±0.4 
6. Test 3 (20mg/kg) 20.3±0.8 21.5±0.4 20.3±0.1 21.5±0.7 
 
Determination of Mean Cell Hemoglobin Concentration (MCHC) 
Table 9: Determination of MCHC 
S.N. Treatment 
(Group) 
MCHC  (g/dl± SEM) 
 1st day           7thday            14th day         21th day 
1. Normal Control 26.2±0.2 26.5±0.1 26.9±0.4 27.2±0.7 
2. Anemic Control 25.8±0.7 25.3±0.5 25.1±0.6 24.6±0.1 
3. Standard (20mg/kg) 26.6±0.1 26.5±0.2 27.3±0.1 28.4±0.5 
4. Test 1 (10mg/kg) 25.5±0.6 25.9±0.3 25.8±0.5 26.7±0.5 
5. Test 2 (15mg/kg) 25.2±0.7 25.9±0.1 26.3±0.5 27.5±0.9 
6. Test 3 (20mg/kg) 26.3±0.2 26.5±0.1 27.3±0.1 27.8±0.7 
 
Determination of White Blood Cells Count (WBC) 
Table 10: Determination of WBC Count- Neutrophils 
S.N. Treatment 
(Group) 
Neutrophils (103/mm3± SEM) 
 1st day           7thday            14th day         21th day 
1. Normal Control 22.2±0.2 22.5±0.1 22.9±0.4 23.4±0.6 
2. Anemic Control 22.8±0.1 22.3±0.3 22.6±0.6 22.3±0.5 
3. Standard (20mg/kg) 22.6±0.1 23.5±0.2 24.3±0.3 25.9±0.6 
4. Test 1 (10mg/kg) 22.5±0.1 22.9±0.2 23.3±0.8 23.7±0.4 
5. Test 2 (15mg/kg) 22.2±0.7 22.5±0.8 22.5±0.7 22.7±0.4 
6. Test 3 (20mg/kg) 22.3±0.4 23.5±0.1 23.3±0.2 24.8±0.3 
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Determination of WBC Count- Basophils 
Table 11: Determination of basophils count 
S.N. Treatment 
(Group) 
Basophils (103/mm3± SEM) 
 1st day           7thday            14th day         21th day 
1. Normal Control 1.0±0.1 1.0±0.3 1.0±0.2 1.0±0.1 
2. Anemic Control 1.0±0.3 1.0±0.4 1.0±0.6 1.0±0.4 
3. Standard (20mg/kg) 1.0±0.7 1.0±0.6 1.0±0.6 1.0±0.7 
4. Test 1 (10mg/kg) 1.0±0.7 1.0±0.2 1.0±0.4 1.0±0.9 
5. Test 2 (15mg/kg) 1.0±0.2 1.0±0.1 1.0±0.7 1.0±0.6 
6. Test 3 (20mg/kg) 1.0±0.1 1.0±0.6 1.0±0.4 1.0±0.2 
 
Determination of WBC Count- Monocytes 
Table 12: Determination of Monocytes 
S.N. Treatment 
(Group) 
Monocytes (103/mm3± SEM) 
 1st day           7thday            14th day         21th day 
1. Normal Control 3.0±0.2 3.1±0.1 3.4±0.6 3.6±0.4 
2. Anemic Control 3.0±0.4 3.1±0.3 2.8±0.5 2.7±0.4 
3. Standard (20mg/kg) 3.1±0.1 3.3±0.1 4.1±0.3 4.7±0.7 
4. Test 1 (10mg/kg) 3.0±0.3 3.0±0.5 3.4±0.3 3.7±0.2 
5. Test 2 (15mg/kg) 3.0±0.1 3.3±0.3 3.6±0.1 3.8±0.6 
6. Test 3 (20mg/kg) 3.1±0.1 3.4±0.4 3.8±0.8 4.2±0.4 
 
 
Determination of WBC Count- Lymphocytes 
Table 13: Determination of Lymphocytes 
S.N. Treatment 
(Group) 
Lymphocytes (103/mm3± SEM) 
 1st day           7thday            14th day         21th day 
1. Normal Control 61.0±0.1 61.4±0.4 62.0±0.7 62.5±0.4 
2. Anemic Control 62.0±0.5 62.4±0.4 61.0±0.6 60.8±0.5 
3. Standard (20mg/kg) 62.0±0.4 63.4±0.7 64.0±0.6 65.2±0.4 
4. Test 1 (10mg/kg) 62.2±0.5 62.8±0.1 62.8±0.8 62.5±0.7 
5. Test 2 (15mg/kg) 62.4±0.8 62.8±0.4 62.4±0.7 63.7±0.4 
6. Test 3 (20mg/kg) 62.0±0.5 63.1±0.4 63.9±0.8 64.7±0.1 
 
Determination of Eosinophil 
Table 14: Determination of Eosinophil 
S.N. Treatment 
(Group) 
Lymphocytes (103/mm3± SEM) 
 1st day           7thday            14th day         21th day 
1. Normal Control 2.8±0.1 3.4±0.8 3.6±0.5 3.9±0.4 
2. Anemic Control 3.2±0.2 3.1±0.6 2.8±0.4 2.8±0.8 
3. Standard (20mg/kg) 3.1±0.8 3.4±0.9 3.8±0.4 4.2±0.7 
4. Test 1 (10mg/kg) 2.8±0.1 3.1±0.4 3.1±0.7 3.5±0.9 
5. Test 2 (15mg/kg) 2.8±0.6 3.1±0.8 3.4±0.7 3.5±0.1 
6. Test 3 (20mg/kg) 2.8±0.4 3.2±0.5 3.7±0.4 3.9±0.4 
 
DISCUSSION 
The physiochemical parameter viz ash content and loss on 
drying  were studied to quantify the medicinal importance of 
drugs ; Acid soluble ash value was compared with water 
soluble ash value and found more. It shows its lipophilic 
nature that influences its absorption. loss on drying shows 
about the water content and volatile substances present in 
the formulation. After incubation the total weight was found 
2.7g that proved that it contains only 0.8g of volatile and 
water contents. In Acute oral toxicity test no significant 
differences in body weight gain were observed No toxic, 
behavioral & mortality changes observed. No altered growth 
or abnormal changes were detected during the macroscopic 
analysis of the rat organs. It demonstrated a safe and 
convenient drug for further use. It assures the safety data 
along with the efficacy. The hematinic movement was 
assessed by surveying different blood parameters like red 
platelet (RBC) tally, hemoglobin (HB) fixation and stuffed cell 
volume (PCV). The mean cell volumes (MCV), mean cell 
hemoglobin (MCH), mean cell hemoglobin focus (MCHC) and 
white platelets (WBC) tally. The parameters were dictated by 
utilizing Auto cell counter 920E (Swelab Ltd). Total 06 
groups were identified and evaluated including Normal 
control, anemic control, standard, test 1, test 2 and test 3. 
They were evaluated for its hematinic potential after 1, 7, 14 
and 21 days. Effect was calculated and compared with the 
standard and control group. They demonstrated a significant 
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level of effect when compared to standard. It proved that the 
marketed ayurvedic formulation possess a significant 
hematinic potential. It showed a dose dependent response 
because maximum response was noted at dose 20mg/kg. It 
also proves about its good preparation and standardization 
of marketed ayurvedic preparation. The standardization and 
pharmacological potential of the product is so significant and 
safe. It assures that this ayurvedic formulation can be further 
used in the treatment of mild to severe anemia. 
CONCLUSION 
In-vivo experimentation revealed safety and good efficacy of 
traditional ayurveda-based therapy for the treatment of 
anaemia. The study needs to be extended to explore other 
traditional preparations and medicinal plants. This 
examination may infer that the lauhabhasma might be 
exceptionally compelling ayurvedic haematinic operator and 
can be helpful in treatment of iron deficiency.  
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